Protalix BioTherapeutics, Inc. (NYSE:PLX – Get Rating) shares were up 3.7% during trading on Tuesday . The company traded as high as $1.96 and last traded at $1.94. Approximately 1,306,325 shares were traded during trading, an increase of 45% from the average daily volume of 900,338 shares. The stock had previously closed at $1.87.
Analysts Set New Price Targets
Separately, StockNews.com started coverage on Protalix BioTherapeutics in a report on Friday, December 16th. They set a “hold” rating on the stock.
Protalix BioTherapeutics Trading Up 3.7 %
The firm has a market cap of $96.52 million, a price-to-earnings ratio of -6.47 and a beta of 1.51. The stock has a 50-day moving average of $1.53 and a 200-day moving average of $1.25.
Protalix BioTherapeutics Company Profile
Protalix Biotherapeutics, Inc is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. Its products include Alidornase alfa, PRX-115 and PRX-11. The company was by Yoseph Shaaltiel in 1993 and is headquartered in Hackensack, NJ.
- Get a free copy of the StockNews.com research report on Protalix BioTherapeutics (PLX)
- Will Q4 Results Send Zoom Video Stock Higher?
- Is Amazon a Blue Chip Stock?
- Occidental Petroleum Pulls Back To The Sweet Spot
- Should You Take a Cruise in Royal Caribbean Stock?
- Is Target Stock Aiming For A Breakout In 2023?
Receive News & Ratings for Protalix BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.